The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.
Following advice received from the company, the timelines for this appraisal are currently to be confirmed.
A further update on timelines will be available in due course.